After Commencement of Commercial Production the Optionee shall, within 45 days after the end of each fiscal quarter, furnish to the Optionor quarterly unaudited statements respecting operations on the Property, together with a statement showing the calculation of Royalty for the fiscal quarter last completed.
After Commencement of Commercial Production on the Property, a Shareholder may unilaterally terminate its participation in this Agreement by delivery of its Common Shares and all of its other securities, if any, that it holds in the capital of MSX to E-38 <PAGE> MSX for cancellation. Such Shareholder shall be liable for any outstanding cash calls and shall post a bond for its proportionate share of any accrued obligation of MSX, including environmental and other mine closure obligations, as determined at the time of such termination. ARTICLE X
After Commencement of Commercial Production. As further described in the Quality Agreement, Genentech shall have the right to have [*] Genentech personnel [*] with operational expertise and another with quality expertise) on-site at the Facility on a full-time basis during all operational hours following the start of Commercial Production to coordinate, expedite and guide the Commercial Runs and Wyeth's performance of its obligations under this Agreement; provided, however, that Genentech shall use its Commercially Reasonable Efforts to assign the same [*] individuals to represent Genentech for the duration of such period so as to minimize the total number of Genentech personnel that are on-site at Wyeth's facility during such period. In addition, Wyeth shall use its Commercially Reasonable Efforts to accommodate up to [*] additional Genentech personnel to be on-site at the Facility on a periodic or part-time basis; provided, however, that, absent Wyeth's request, Genentech shall use its Commercially Reasonable Efforts to minimize the total number of different Genentech personnel that are on-site at the Facility for the duration of such period so as to minimize the impact of their presence in the Facility on Wyeth's operations. Subject to Wyeth's approval, such approval not to be unreasonably withheld or delayed, Genentech shall have the right to designate a reasonable number of additional Genentech personnel to be present at the Facility during Commercial Production on a periodic or part-time basis. Unless otherwise agreed by Wyeth, such representatives of Genentech shall have access to all areas of the Facility as are relevant to the manufacture, storage and/or quality testing of the Product, as well as cafeterias, designated office space and public areas. All Genentech personnel at the Facility shall comply with all Wyeth policies and procedures. In the event any Genentech personnel assigned to the Facility fail to comply with any applicable Wyeth policy or procedure, Genentech, upon Wyeth's request, shall immediately replace such personnel.
After Commencement of Commercial Production the Purchaser shall, within 60 days after the end of each fiscal quarter, furnish to the Royalty Holder quarterly unaudited statements respecting operations on the Property, together with a statement showing the calculation of Royalty for the fiscal quarter last completed.
After Commencement of Commercial Production. Cap-Ex will, within 120 days of the end of Cap-Ex’s financial year, provide Mandu Resources with an audited statement (the “Royalty Statement”) of the royalty payments made to Mandu Resources in the previous financial year.
After Commencement of Commercial Production. Cap-Ex will, within 120 days of the end of Cap-Ex’s financial year, provide Numco with an audited statement (the “Royalty Statement”) of the royalty payments made to Numco in the previous financial year.
After Commencement of Commercial Production. As further described in the Quality Agreement, Genentech shall have the right to designate at its discretion up to [*] of its personnel (and such additional personnel in such numbers as may be agreed to by the parties or as otherwise required to implement a decision made pursuant to Section 3.1.4) to be present in the Lonza Facility during all operational hours during the Term of this Agreement to coordinate, expedite and guide the Commercial Runs and Lonza’s performance of its obligations under this Agreement. While at the Lonza Facility, such representative of Genentech shall have access to all areas as are relevant to the manufacture, storage and or quality testing of the Bulk Product, cafeterias, designated office space and public areas, or as otherwise authorized by Lonza, and shall comply with all applicable Lonza policies and procedures.
